SURVEILLANCE FOR POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE USE OF INTRAVITREAL BEVACIZUMAB FOR RETINAL AND CHOROIDAL VASCULAR DISEASE

Abstract

Intraocular bevacizumab appears to be well tolerated for the treatment of a variety of retinal and choroidal vascular diseases. RPE tears may occur when treating choroidal neovascularization, particularly in patients with preexisting RPE detachment.